KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations: 2009-2025

Historic Cash from Operations for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Cash from Operations rose 10.85% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 535.51%. This contributed to the annual value of $31.5 million for FY2024, which is 647.99% up from last year.
  • Rigel Pharmaceuticals' Cash from Operations amounted to $24.0 million in Q3 2025, which was down 21.31% from $30.5 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Cash from Operations registered a high of $55.2 million during Q2 2021, and its lowest value of -$25.6 million during Q1 2022.
  • For the 3-year period, Rigel Pharmaceuticals' Cash from Operations averaged around $7.2 million, with its median value being $302,000 (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 545.17% in 2021, then spiked by 10,011.59% in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Cash from Operations stood at -$19.1 million in 2021, then declined by 14.79% to -$21.9 million in 2022, then spiked by 71.52% to -$6.2 million in 2023, then surged by 332.42% to $14.5 million in 2024, then rose by 10.85% to $24.0 million in 2025.
  • Its Cash from Operations was $24.0 million in Q3 2025, compared to $30.5 million in Q2 2025 and -$893,000 in Q1 2025.